Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary Generalized Epilepsies.

Murphy1, Delanty

  • 1Department of Clinical Neurological Sciences, Royal College of Surgeons in Ireland and Beaumont Hospital, PO Box 1297, Beaumont Road, Dublin 9, Ireland.

Current Treatment Options in Neurology
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rules for the Administration of Chloroform in Labor.

Iowa medical journal·2023
Same author

On Certain Forms of Headache.

The North-Western medical and surgical journal·2023
Same author

Twins Locked in Each Other.

The North-Western medical and surgical journal·2023
Same author

Report on the Use of Apomorphia in Sunstroke.

The Indian medical gazette·2017
Same author

Pharmacokinetic profile of rectally administered diclofenac sodium in children undergoing adenotonsillectomy

Paediatric anaesthesia·2000
Same author

Protease Inhibitors Therapy for AIDS Patients.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases·2000
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Ethosuximide is the first choice for childhood absence epilepsy, while valproic acid is preferred for juvenile absence and myoclonic epilepsy. Treatment selection depends on seizure type, patient factors, and potential side effects, with lifelong therapy often necessary.

Area of Science:

  • Neurology
  • Epileptology
  • Pharmacology

Background:

  • Childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizure on awakening (EGA) are distinct epilepsy syndromes.
  • Treatment guidelines vary based on epilepsy type, with specific antiepileptic drugs (AEDs) showing differential efficacy and safety profiles.

Purpose of the Study:

  • To review and summarize the current evidence regarding the first-line and alternative antiepileptic drug (AED) treatments for various epilepsy syndromes.
  • To highlight the efficacy, toxicity, and specific considerations for AED selection in CAE, JAE, JME, and EGA.

Main Methods:

  • Literature review of established and newer antiepileptic drugs (AEDs) for specific epilepsy types.
  • Analysis of drug efficacy, side effect profiles, and clinical considerations for monotherapy and add-on treatments.

Related Experiment Videos

Main Results:

  • For CAE, ethosuximide (ESM) is first-line; valproic acid (VPA) and lamotrigine (LTG) are alternatives. For JAE and JME, VPA is often first-line, with LTG and topiramate (TPM) as alternatives, though VPA's teratogenicity is a concern. For EGA, VPA is preferred, especially with co-occurring absence or myoclonic seizures; other options include phenobarbital (PB), phenytoin (PHT), carbamazepine (CBZ), LTG, and TPM.
  • Certain AEDs like carbamazepine (CBZ), oxcarbazepine (OXC), and vigabatrin (VGB) can worsen absence or myoclonic seizures. Newer AEDs have limited data for specific epilepsy types.
  • Lifelong antiepileptic drug (AED) therapy is generally necessary for JME and EGA, but not typically anticipated for CAE.

Conclusions:

  • AED selection requires careful consideration of epilepsy syndrome, seizure semiology, patient age, gender, and potential adverse effects.
  • Valproic acid remains a cornerstone for several epilepsy types but carries risks, particularly teratogenicity. Newer agents offer alternatives but require further study.
  • Optimizing AED therapy involves balancing efficacy with tolerability and safety, especially in specific populations like women of childbearing age and during pregnancy.